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asodilator Therapy for
ecompensated Heart Failure*
lyde W. Yancy, MD, FACC, FAHA, FACP
allas, Texas
What was once old is now new again
—Author unknown
odium nitroprusside (SNP) has been available as a parenteral
gent in cardiovascular medicine for 30 years. It exists as a
ianion [Fe(CN)5NO]
2 in which the iron moiety is an
ctahedral surrounded by 5 cyanide ligands and 1 nitric oxide
igand. Its mechanism of action is the liberation of nitric oxide,
hich is accompanied by the release of cyanide ions (1).
See page 200
odium nitroprusside is appropriate for the acute treatment
f congestive heart failure. The starting dose is 0.3 to 0.5
g/kg/min titrated to goal attainment of desired hemody-
amics but usually not beyond 5 g/kg/min. Doses of 10
g/kg/min or sustained administration will result in exces-
ive cyanide production, which may occasionally lead to
yanide poisoning and may rarely lead to the development
f methemoglobinemia. Both conditions require immediate
ntervention with cessation of the infusion and/or initiation
f hemodialysis and possibly administration of thiosulfate or
ethylene blue. When used for heart failure, placement of
right heart catheter is appropriate to monitor the response
o SNP therapy. Given these several circumstances, the use
f this older drug has yielded to newer treatments for heart
ailure (2).
In this issue of the Journal, Mullens et al. (3) have
ublished their experience regarding the use of SNP for
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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ational Heart, Lung, and Blood Institute (member, study section, clinical and
ntegrative cardiovascular science).he management of advanced decompensated heart fail-
re. These retrospective, single-center, nonrandomized
ata represent the first recent database to revisit the
otential salutary benefits of SNP as vasoactive therapy in
he setting of decompensated heart failure. The data were
btained in a highly selected patient cohort characterized
y advanced heart failure with low cardiac output and
ncreased vascular resistance. The adjunctive use of SNP
ielded an excellent acute hemodynamic response and
as associated with a neutral, if not favorable, interme-
iate term effect when the acute use of SNP was followed
y optimal use of evidence-based medical therapy, in-
luding oral vasodilator therapy. Specifically, the use of
sosorbide dinitrate and hydralazine in addition to
ngiotensin-converting enzyme I or angiotensin-receptor
locker plus beta-blocker increased from 26% or 16%,
espectively, at admission to 48% for combined vasodila-
or therapy at discharge. It is provocative to view these
ndings in context with other data (i.e., A-HeFT [Afri-
an American Heart Failure Trial]) as further evidence
hat nitric oxide bioavailability is important in heart
ailure (4).
As noted in the Heart Failure Society of America 2006
omprehensive Heart Failure Practice Guideline, the use of
of 3 vasodilators—nitroglycerin, sodium nitroprusside, or
esiritide—is prompted, that is, “may be considered,” for
cute decompensated heart failure (ADHF) with symptoms
t rest in the absence of hypotension when acute relief of
yspnea is a goal of therapy (5). These compounds are
ntended to be given as adjunctive therapy for background
iuretic therapy. The use of vasodilator therapy, specifically
itroglycerin and nesiritide, has been associated with an
mmediate reduction in filling pressures and relief of dys-
nea (6), but certain safety questions regarding nesiritide
ave been noted (7,8). Newer agents, such as arginine-
asopressin antagonists, with vasodilator properties have
lso demonstrated a prompt reduction of filling pressures,
elief of dyspnea, and sustained weight loss consistent with
econgestion (9,10). To date, however, none of these agents
as been associated with an improvement in outcomes of
DHF. Importantly, the data supporting SNP emanate not
rom clinical trial data but principally from 30 years of
linical use by experienced physicians, that is, from “con-
ensus opinion.”
Early data from Cohn and Burke (11) introduced the
ationale for vasodilation in heart failure. Subsequently,
tevenson (12) helped to establish the benefit of SNP in
atients with advanced heart failure—specifically, transplant-
ligible patients with New York Heart Association functional
lass IV symptoms and a phenotype of increased vascular
esistance and marginal cardiac output. In patients instru-
ented with a right heart catheter, SNP was used to effect
tailored therapy” with targeted goal reductions in pulmonary
apillary wedge pressure, central venous pressure, and systemic
ascular resistance while preserving blood pressure and achiev-
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July 15, 2008:208–10 Editorial Commentng an adequate cardiac index. Once certain hemodynamic
argets were reached, conversion to oral therapy ensued. For
hose patients with advanced heart failure, the attainment of
ailored therapy goals yielded a 1-year survival that was
quivalent to the prevailing 1-year survival after transplant (12).
odium nitroprusside also has an indication for hypertensive
mergency (13,14), may be paradoxically beneficial for critical
ortic stenosis (14), and facilitates the management of acute
ortic or mitral insufficiency where prompt afterload reduction
esults in hemodynamic stabilization.
Despite this portfolio of efficacy for several cardiovascular
isease states, the use of SNP has been relegated to a historical
ootnote. Why has this occurred when the benefit in several
linical scenarios is apparent, the safety profile is manageable,
nd the magnitude of its acute efficacy for decompensated heart
ailure is possibly greater than other parenterally administered
ompounds? As a generic compound, there is no marketing
ffort for SNP; the requirement for invasive hemodynamic
onitoring is a very legitimate hindrance; and the real but
nfrequent risk of cyanide toxicity generates concern. However,
erhaps it is time to revive this older agent as a “new” modality
or certain patients with decompensated heart failure.
Recently, the best synthesis of the pathophysiology of
cute decompensated heart failure has been a hemodynamic
efinition based on evidence of congestion, that is, increased
reload (15,16). This concept does not identify the correct
iological pathophysiology, and indeed, the heterogeneity of
DHF would suggest that multiple basic mechanisms are
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ng of our hemodynamic construct to consider congestion as
he primary hemodynamic malady in ADHF is not unwar-
anted. However, the extension of that concept to specifi-
ally implicate volume overload has yielded an overbearing
mphasis on “decongestion,” which is usually accomplished
ith diuretic administration that is sometimes given in
onsiderable doses with increasing evidence that such may
ot be entirely without risk.
A more comprehensive description of the pathophysiol-
gy of ADHF might focus instead on left and/or right atrial
ypertension with volume overload as only 1 of the contrib-
tors to this hemodynamic perturbation. By focusing on
trial hypertension, a more global appreciation of the myriad
f hemodynamic models in ADHF could be considered.
pecifically, increased afterload with concomitant low or mar-
inal cardiac outputs, abnormal left/right ventricle compliance,
nd significant atrioventricular valvular regurgitation are all
lausible explanations for ADHF that vary from a volume
verload model. Of these additional hemodynamic profiles,
iuretic therapy alone is not likely to be of sufficient benefit.
owever, the selective use of vasodilator therapy, in con-
unction with a regimen of decongestion, more appropri-
tely addresses this broader spectrum of hemodynamic
isruptions in ADHF. See Figure 1 for a proposed broader
ased treatment algorithm for ADHF.
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Editorial Comment July 15, 2008:208–10dvanced heart failure and borderline systemic blood pressure
n whom a reasonable indication exists for right heart cathe-
erization, a hemodynamic profile of marginal cardiac output,
igh filling pressures, and elevated systemic vascular resistance
r peripheral vascular resistance should prompt consideration
or diuretics plus vasodilator therapy. Based on the present
ata, SNP is a reasonable option for these patients. The
utcome data from Mullens et al. (3) are provocative but
hould be taken with measured reserve. This is a highly
elected patient population treated in a tertiary care center
resumably with very appropriate outpatient follow-up. The
bserved “benefit” may indeed have been due to the use of
NP, but the impact of a structured disease management
rogram, the adverse effect of any inotropic exposure in the
ontrol group, and the curious benefit of adjunctive isosorbide
initrate/hydralazine (race neutral) mute any significant enthu-
iasm for a unique intermediate-term benefit of SNP. Such an
bservation should be reserved for findings from a larger
rospective randomized controlled trial.
What are the lessons learned from this experience?
. Sodium nitroprusside is a reasonable therapeutic inter-
vention in patients with advanced heart failure who are
hospitalized with decompensation and have undergone
right heart catheterization with evidence of a hemody-
namic profile consistent with both increased preload
(congestion) and increased afterload.
. In experienced hands and for selected patients, right heart
catheterization remains a reasonable diagnostic intervention
and yields “biomarkers” appropriate to titration therapy.
. Maximal use of evidence-based regimens for heart failure
including combined vasodilator therapy (isosorbide dini-
trate/hydralazine, race-irrespective) in the setting of careful
medical management yields reasonable, if not good, out-
comes even in patients with advanced heart failure.
. There may be benefit of nitric oxide enhancement in
both acute and chronic models of heart failure.
Several limitations must also be acknowledged: we remain
ithout randomized multicenter data regarding the use of
NP for ADHF; the process of care delivery systems required
o safely administer SNP and proceed with close pulmonary
rtery catheter/hemodynamic monitoring are very center-
pecific; the selection of patients for right heart catheterization
s somewhat subjective; we do not have a reasonable noninva-
ive alternative to right heart catheterization; the ESCAPE
Evaluation Study of Congestive Heart Failure and Pulmonary
rtery Catheterization Effectiveness) study data (17) dissuad-
ng routine use of right heart catheterization are inescapable;
nd greater use of SNP is likely to be associated with an
ncrease in the occurrence of cyanide toxicity—a potentially
orbid complication. Yet, broader use of SNP now appears to
e a more palatable consideration for patients with decompen-
ated advanced heart failure.
While we continue to search for a treatment panacea for
DHF, we should perhaps recognize the hemodynamicomplexity of the disease, broaden our hemodynamic modelo include conditions of both increased preload and in-
reased afterload, expand the treatment regimen to include
greater use of vasodilator therapy, and acknowledge that a
rug older than most interns but tried and tested over
everal different eras of cardiovascular medicine may still be
f considerable benefit for heart failure. It is possible that
what was once old is now new again” for ADHF.
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